Form 4: Insider Sells Shares in Crinetics Pharmaceuticals

Jeff E. Knight, Chief Development & Operating Officer of Crinetics Pharmaceuticals, Inc., reported the sale of 85,163 shares of common stock on April 8, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Jeff E. Knight, Chief Development & Operating Officer of Crinetics Pharmaceuticals, Inc., sold 85,163 shares of common stock on April 8, 2026.
• The sale was conducted through open market transactions at a volume-weighted average price of $40.10 per share, with prices ranging from $40.00 to $40.34.
• This transaction was executed automatically under a Rule 10b5-1 trading plan adopted by Mr. Knight on December 12, 2025.
• Following the sale, Mr. Knight beneficially owns 105,289 shares of common stock.
• The filing also details the acquisition of shares through stock options, with varying vesting schedules and exercise prices.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale by a key executive, despite the transaction being conducted under a pre-defined plan.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to stock disposition rather than a reaction to immediate negative news.
• The sale occurred at a volume-weighted average price of $40.10, suggesting a favorable market price at the time of the transaction.
• Mr. Knight continues to beneficially own a significant number of shares (105,289) after the sale, indicating continued alignment with the company's performance.

Negatives

• A significant number of shares (85,163) were sold by a key executive, which could be perceived negatively by the market.
• The sale represents a reduction in the insider's direct ownership stake in the company.

Risks

• The sale of a substantial number of shares by an executive could signal a lack of confidence in future stock performance, although it was conducted under a Rule 10b5-1 plan.
• Future vesting of stock options could lead to further selling pressure if executives choose to diversify their holdings.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future financial performance. It primarily details insider transactions.

Management Comments

• The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
• The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34.
• Detailed information on the exact number of shares can be obtained from the Issuer upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is a common event in the biotechnology and pharmaceutical sectors as executives manage personal diversification and compensation. The key is to assess the volume relative to total holdings and the context of the plan.

Stakeholder Impact

• Shareholders: May perceive the sale as a negative signal, potentially impacting short-term stock price, though the Rule 10b5-1 plan mitigates this concern to some extent.
• Employees: May view the sale by a senior officer with mixed feelings, depending on their own confidence in the company's future.
• Management: The transaction is part of a planned strategy for personal financial management.

Next Steps

• Monitor future filings for any additional insider transactions.
• Observe the company's performance and any public statements to understand the broader context of insider selling.

Key Dates

Recommendation

The filing reports a significant sale by a key executive, which can be a negative indicator. However, the sale was executed under a Rule 10b5-1 trading plan, suggesting it was pre-planned and not necessarily a reflection of immediate negative sentiment. Without further context on the company's performance or strategic outlook, a 'hold' recommendation is prudent, advising investors to await more substantive news.

Keywords

Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Crinetics Pharmaceuticals, Jeff E. Knight, Beneficial Ownership, Stock Options, SEC Filing